Startseite Kongressberichte 2021 2021 ASCO Annual Meeting Gynaecological Cancer Gynecologic Cancer

Gynecologic Cancer

Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study.
 
Felix Blanc-Durand, Elisa Yaniz, Catherine Genestie, et al.
 
 
Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial.
 
Patricia Pautier, Philipp Harter, Carmela Pisano, et al.
 Clinical trial information: NCT02477644
 
Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.
 
Cara Amanda Mathews, Fiona Simpkins, Karen Anne Cadoo, et al.
Clinical trial information: NCT02983799
 
Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.
 
Stephanie L. Wethington, Payal D Shah, Lainie P. Martin, et al.
Clinical trial information: NCT03462342
 
Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.
 
Amit M. Oza, Alla Sergeevna Lisyanskaya, Alexander A. Fedenko, et al.
 Clinical trial information: NCT02855944
 
Niraparib efficacy and safety in patients with BRCA mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials.
 
Antonio Gonzalez Martin, Ursula A. Matulonis, Jacob Korach, et al.
Clinical trial information: NCT02655016,  NCT01847274,  NCT03705156
 
Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).
 
Rachel N. Grisham, Ignace Vergote, Susana N. Banerjee, et al.
Clinical trial information: NCT01849874
 
An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION).
 
JUNG-YUN LEE, Byoung-Gie Kim, Jae-Weon Kim, et al.
 Clinical trial information: NCT03699449
 
Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial.
 
Lukas Rob, David Cibula, Pawel Knapp, et al.
 Clinical trial information: NCT02107937
 
Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
 
Judith Michels, François Ghiringhelli, Jean-Sebastien Frenel, et al.
Clinical trial information: NCT03596281
 
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
 
Dana M Roque, Stefania Bellone, Eric R. Siegel, et al.
 Clinical trial information: NCT02899793
 
Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.
 
Qin Xu, Chuanben Chen, Yang Sun, et al.